These 10 Firms Took A Hit on Friday

8. Immunitybio Inc. (NASDAQ:IBRX)

Shares of Immunitybio Inc. (IBRX) retreated on Friday, losing 3.29 percent to end at $2.94 apiece as investors resorted to profit-taking following Thursday’s surge.

Earlier this week, it can be learned that the company announced plans to submit multiple treatments for approval by the Food and Drug Administration in 2025.

Late Wednesday, Immunitybio (IBRX) said it would submit a supplemental biologics license application (BLA) for the treatment of bladder cancer. If approved by the FDA, the BLAs will allow the company to sell its products across the US.

In addition, it would also submit another BLA for the treatment of patients with a certain type of lung cancer.

ImmunityBio, Inc. (IBRX) said that a Phase 2B study had already indicated positive results for patients whose first and second treatment attempts ended unsuccessfully after using the company’s Anktiva drug in combination with other inhibitors.